This company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsCrescita Therapeutics（CRRT.F）株式概要皮膚科会社であるクレシタ・セラピューティクス社は、カナダ、米国、および国際的に、非処方用スキンケア製品と処方薬製品を提供している。 詳細CRRT.F ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析過去5年間で収益は年間22.4%減少しました。 株式の流動性は非常に低い 意味のある時価総額がありません ( $11M )すべてのリスクチェックを見るCRRT.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.5678.3% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-13m28m2016201920222025202620282031Revenue CA$28.3mEarnings CA$4.2mAdvancedSet Fair ValueView all narrativesCrescita Therapeutics Inc. 競合他社BiofronteraSymbol: NasdaqCM:BFRIMarket cap: US$13.8mNuminus WellnessSymbol: OTCPK:NUMI.FMarket cap: US$6.7mInMed PharmaceuticalsSymbol: NasdaqCM:INMMarket cap: US$6.7mChina SXT PharmaceuticalsSymbol: NasdaqCM:SXTCMarket cap: US$15.4m価格と性能株価の高値、安値、推移の概要Crescita Therapeutics過去の株価現在の株価CA$0.5652週高値CA$0.5752週安値CA$0.021ベータ-0.151ヶ月の変化-0.23%3ヶ月変化n/a1年変化n/a3年間の変化n/a5年間の変化-11.04%IPOからの変化-51.95%最新ニュースお知らせ • Jun 04ClinActiv Holdings Inc. completed the acquisition of Crescita Therapeutics Inc. (TSX:CTX).ClinActiv Holdings Inc. entered into a definitive arrangement agreement to acquire Crescita Therapeutics Inc. (TSX:CTX) for CAD 15.4 million on March 14, 2026. A cash consideration of CAD 15.4 million valued at CAD 0.8 per share will be paid by the buyer, subject to upward or downward adjustment based on the Company’s net working capital balance at the closing of the Arrangement, subject to a minimum purchase price of CAD 0.75 per Share. As part of consideration, CAD 15.4 million is paid towards common equity of Crescita Therapeutics Inc. The Arrangement Agreement includes a termination fee of CAD 2.0 million, and reverse termination fee of CAD 2.1 million ($1.5 million). The deal is subject to approval by shareholders of Crescita Therapeutics Inc. and receipt of court approval, and other customary conditions, Dissent Rights and minimum closing net cash. The transaction has been unanimously approved by the board of directors of Crescita Therapeutics and recommended that shareholders vote for the arrangement. The Arrangement is conditional on the Company having minimum cash and net working capital balances at closing. The deal is expected to close in the second quarter of 2026. As of April 22, 2026, Crescita Therapeutics Inc. filed and mailed shareholder meeting materials in connection with a special meeting to be held on May 14, 2026, seeking shareholder approval of the proposed arrangement with ClinActiv Holdings Inc. On May 14, 2026, the shareholders of Crescita Therapeutics approved the transaction. On May 20, 2026, Crescita Therapeutics Inc. announced that it has obtained a final court order from the Ontario Superior Court of Justice (Commercial List) approving the transaction. Upon closing of the arrangement, it is expected that the Crescita Therapeutics shares will be delisted from the Toronto Stock Exchange and that it will apply to the applicable Canadian securities regulators to cease to be a reporting issuer under applicable Canadian securities laws. As of June 1, 2026, the final consideration payable to the shareholders of Crescita is $0.8 per share and the transaction is expected to close on June 3, 2026. Bloom Burton Securities Inc. acted as financial advisor and fairness opinion provider for Crescita Therapeutics Inc. Chris Sunstrum of Goodmans LLP acted as legal advisor for Crescita Therapeutics Inc. BCF LLP acted as legal advisor for Crescita Therapeutics Inc. Aaron Sonshine of Bennett Jones LLP is acting as legal advisor to ClinActiv Holdings. TSX Trust Company acted as depositary bank to Crescita Therapeutics. ClinActiv Holdings Inc. completed the acquisition of Crescita Therapeutics Inc. (TSX:CTX) on June 3, 2026.お知らせ • May 17Crescita Therapeutics Expects its Shares to Be Delisted from the Toronto Stock Exchange Upon Closing of the ArrangementCrescita Therapeutics Inc. (the “Company”) announced that at its special meeting (the “Meeting”) of shareholders (the “Shareholders”) held in person on May 14, 2026, Shareholders voted overwhelmingly in favour of the special resolution (the “Arrangement Resolution”) approving the previously announced plan of arrangement (the “Arrangement”) involving the Company, ClinActiv Holdings Inc. and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser will acquire all of the issued and outstanding common shares of the Company (the “Shares”) in exchange for all-cash consideration, subject to the terms and conditions of the arrangement agreement dated March 14, 2026 (the “Arrangement Agreement”). The final order of the Ontario Superior Court of Justice (Commercial List) approving the Arrangement will be sought on May 20, 2026. Completion of the Arrangement remains subject to receipt of the final order, the Company having the minimum cash and net working capital balances at closing, as well as other customary closing conditions. As of May 14, 2026, the Company anticipates that the Arrangement will be completed in the second quarter of 2026. Upon closing of the Arrangement, it is expected that the Shares will be delisted from the Toronto Stock Exchange and that the Company will apply to the applicable Canadian securities regulators to cease to be a reporting issuer under applicable Canadian securities laws.お知らせ • Mar 16ClinActiv Holdings Inc. entered into a definitive arrangement agreement to acquire Crescita Therapeutics Inc. (TSX:CTX) for CAD 15.4 million.ClinActiv Holdings Inc. entered into a definitive arrangement agreement to acquire Crescita Therapeutics Inc. (TSX:CTX) for CAD 15.4 million on March 16, 2026. A cash consideration of CAD 15.4 million valued at CAD 0.8 per share will be paid by the buyer, subject to upward or downward adjustment based on the Company’s net working capital balance at the closing of the Arrangement, subject to a minimum purchase price of CAD 0.75 per Share. As part of consideration, CAD 15.4 million is paid towards common equity of Crescita Therapeutics Inc. The Arrangement Agreement includes a termination fee of CAD 2.0 million, and reverse termination fee of CAD 2.1 million ($1.5 million). The deal is subject to approval by shareholders of Crescita Therapeutics Inc. and receipt of court approval, and other customary conditions. The Arrangement is conditional on the Company having minimum cash and net working capital balances at closing. The Board of Crescita Therapeutics Inc unanimously recommended that shareholders vote FOR the Arrangement. The deal is is expected to close in the second quarter of 2026. Bloom Burton Securities Inc. acted as financial advisor and fairness opinion provider for Crescita Therapeutics Inc. Goodmans LLP acted as legal advisor for Crescita Therapeutics Inc. BCF LLP acted as legal advisor for Crescita Therapeutics Inc. Bennett Jones LLP is acting as legal advisor to ClinActiv Holdings.お知らせ • Mar 17Crescita Therapeutics Inc., Annual General Meeting, Jun 04, 2025Crescita Therapeutics Inc., Annual General Meeting, Jun 04, 2025.お知らせ • Jun 27Crescita Therapeutics Inc. (TSX:CTX) completed the acquisition of Assets of Occy Laboratory for CAD 0.9 million.Crescita Therapeutics Inc. (TSX:CTX) agreed to acquire Assets of Occy Laboratory on June 20, 2024.The transaction was approved by the bankruptcy court, is subject only to customary closing conditions, and is expected to close thereafter. Crescita Therapeutics Inc. (TSX:CTX) completed the acquisition of Assets of Occy Laboratory for CAD 0.9 million on June 26, 2024.お知らせ • Mar 15Crescita Therapeutics Inc., Annual General Meeting, Jun 05, 2024Crescita Therapeutics Inc., Annual General Meeting, Jun 05, 2024.最新情報をもっと見るRecent updatesお知らせ • Jun 04ClinActiv Holdings Inc. completed the acquisition of Crescita Therapeutics Inc. (TSX:CTX).ClinActiv Holdings Inc. entered into a definitive arrangement agreement to acquire Crescita Therapeutics Inc. (TSX:CTX) for CAD 15.4 million on March 14, 2026. A cash consideration of CAD 15.4 million valued at CAD 0.8 per share will be paid by the buyer, subject to upward or downward adjustment based on the Company’s net working capital balance at the closing of the Arrangement, subject to a minimum purchase price of CAD 0.75 per Share. As part of consideration, CAD 15.4 million is paid towards common equity of Crescita Therapeutics Inc. The Arrangement Agreement includes a termination fee of CAD 2.0 million, and reverse termination fee of CAD 2.1 million ($1.5 million). The deal is subject to approval by shareholders of Crescita Therapeutics Inc. and receipt of court approval, and other customary conditions, Dissent Rights and minimum closing net cash. The transaction has been unanimously approved by the board of directors of Crescita Therapeutics and recommended that shareholders vote for the arrangement. The Arrangement is conditional on the Company having minimum cash and net working capital balances at closing. The deal is expected to close in the second quarter of 2026. As of April 22, 2026, Crescita Therapeutics Inc. filed and mailed shareholder meeting materials in connection with a special meeting to be held on May 14, 2026, seeking shareholder approval of the proposed arrangement with ClinActiv Holdings Inc. On May 14, 2026, the shareholders of Crescita Therapeutics approved the transaction. On May 20, 2026, Crescita Therapeutics Inc. announced that it has obtained a final court order from the Ontario Superior Court of Justice (Commercial List) approving the transaction. Upon closing of the arrangement, it is expected that the Crescita Therapeutics shares will be delisted from the Toronto Stock Exchange and that it will apply to the applicable Canadian securities regulators to cease to be a reporting issuer under applicable Canadian securities laws. As of June 1, 2026, the final consideration payable to the shareholders of Crescita is $0.8 per share and the transaction is expected to close on June 3, 2026. Bloom Burton Securities Inc. acted as financial advisor and fairness opinion provider for Crescita Therapeutics Inc. Chris Sunstrum of Goodmans LLP acted as legal advisor for Crescita Therapeutics Inc. BCF LLP acted as legal advisor for Crescita Therapeutics Inc. Aaron Sonshine of Bennett Jones LLP is acting as legal advisor to ClinActiv Holdings. TSX Trust Company acted as depositary bank to Crescita Therapeutics. ClinActiv Holdings Inc. completed the acquisition of Crescita Therapeutics Inc. (TSX:CTX) on June 3, 2026.お知らせ • May 17Crescita Therapeutics Expects its Shares to Be Delisted from the Toronto Stock Exchange Upon Closing of the ArrangementCrescita Therapeutics Inc. (the “Company”) announced that at its special meeting (the “Meeting”) of shareholders (the “Shareholders”) held in person on May 14, 2026, Shareholders voted overwhelmingly in favour of the special resolution (the “Arrangement Resolution”) approving the previously announced plan of arrangement (the “Arrangement”) involving the Company, ClinActiv Holdings Inc. and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser will acquire all of the issued and outstanding common shares of the Company (the “Shares”) in exchange for all-cash consideration, subject to the terms and conditions of the arrangement agreement dated March 14, 2026 (the “Arrangement Agreement”). The final order of the Ontario Superior Court of Justice (Commercial List) approving the Arrangement will be sought on May 20, 2026. Completion of the Arrangement remains subject to receipt of the final order, the Company having the minimum cash and net working capital balances at closing, as well as other customary closing conditions. As of May 14, 2026, the Company anticipates that the Arrangement will be completed in the second quarter of 2026. Upon closing of the Arrangement, it is expected that the Shares will be delisted from the Toronto Stock Exchange and that the Company will apply to the applicable Canadian securities regulators to cease to be a reporting issuer under applicable Canadian securities laws.お知らせ • Mar 16ClinActiv Holdings Inc. entered into a definitive arrangement agreement to acquire Crescita Therapeutics Inc. (TSX:CTX) for CAD 15.4 million.ClinActiv Holdings Inc. entered into a definitive arrangement agreement to acquire Crescita Therapeutics Inc. (TSX:CTX) for CAD 15.4 million on March 16, 2026. A cash consideration of CAD 15.4 million valued at CAD 0.8 per share will be paid by the buyer, subject to upward or downward adjustment based on the Company’s net working capital balance at the closing of the Arrangement, subject to a minimum purchase price of CAD 0.75 per Share. As part of consideration, CAD 15.4 million is paid towards common equity of Crescita Therapeutics Inc. The Arrangement Agreement includes a termination fee of CAD 2.0 million, and reverse termination fee of CAD 2.1 million ($1.5 million). The deal is subject to approval by shareholders of Crescita Therapeutics Inc. and receipt of court approval, and other customary conditions. The Arrangement is conditional on the Company having minimum cash and net working capital balances at closing. The Board of Crescita Therapeutics Inc unanimously recommended that shareholders vote FOR the Arrangement. The deal is is expected to close in the second quarter of 2026. Bloom Burton Securities Inc. acted as financial advisor and fairness opinion provider for Crescita Therapeutics Inc. Goodmans LLP acted as legal advisor for Crescita Therapeutics Inc. BCF LLP acted as legal advisor for Crescita Therapeutics Inc. Bennett Jones LLP is acting as legal advisor to ClinActiv Holdings.お知らせ • Mar 17Crescita Therapeutics Inc., Annual General Meeting, Jun 04, 2025Crescita Therapeutics Inc., Annual General Meeting, Jun 04, 2025.お知らせ • Jun 27Crescita Therapeutics Inc. (TSX:CTX) completed the acquisition of Assets of Occy Laboratory for CAD 0.9 million.Crescita Therapeutics Inc. (TSX:CTX) agreed to acquire Assets of Occy Laboratory on June 20, 2024.The transaction was approved by the bankruptcy court, is subject only to customary closing conditions, and is expected to close thereafter. Crescita Therapeutics Inc. (TSX:CTX) completed the acquisition of Assets of Occy Laboratory for CAD 0.9 million on June 26, 2024.お知らせ • Mar 15Crescita Therapeutics Inc., Annual General Meeting, Jun 05, 2024Crescita Therapeutics Inc., Annual General Meeting, Jun 05, 2024.株主還元CRRT.FUS PharmaceuticalsUS 市場7D0%0.04%-2.3%1Yn/a38.9%21.2%株主還元を見る業界別リターン: CRRT.FがUS Pharmaceuticals業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: CRRT.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is CRRT.F's price volatile compared to industry and market?CRRT.F volatilityCRRT.F Average Weekly Movementn/aPharmaceuticals Industry Average Movement10.4%Market Average Movement7.2%10% most volatile stocks in US Market16.7%10% least volatile stocks in US Market3.1%安定した株価: CRRT.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のCRRT.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト201665Serge Verreaultwww.crescitatherapeutics.com皮膚科のクレシタ・セラピューティクス社は、カナダ、米国、および国際的に非処方箋のスキンケア製品と処方箋医薬品を提供している。事業セグメントは3つ：商業用スキンケア、ライセンスおよびロイヤルティ、製造およびサービス。同社は、Multiplexed Molecular Penetration Enhancers（多重分子浸透促進剤）やDuraPeel（デュラピール）といった独自のプラットフォーム技術を保有しており、有効成分を皮膚に、あるいは皮膚を通して送達しやすくする特許製剤の開発をサポートしている。同社の医療用製品には、表面的な皮膚科学的処置の前に無傷の皮膚に皮膚鎮痛作用をもたらす局所局所麻酔クリーム「Pliaglis」、MMPE技術とコルチコステロイドを併用した、尋常性乾癬を治療するための第III相外用製剤「CTX-101」、MMPE技術を利用した、未発表の皮膚科学的皮膚疾患を治療するための第I相外用製剤「CTX-102」、および皮膚疾患の処方治療用にMMPE技術を利用した前臨床製剤中の皮膚科学製品がある。非処方用製品では、Laboratoire Dr RenaudおよびAquafoliaブランドで、軽度のにきび、老化、脱水、色素沈着、敏感肌、酒さなどを治療するためのフェイスクリーム、クレンジング、角質除去剤、マスク、美容液、サンケアなどの皮膚化粧品、Pro-DermおよびAlyriaブランドで、非侵襲的・低侵襲的処置やスキンケア治療のためのメディカルエステティックを提供している。また、肌活性化ソリューションNCTF Boost 135 HA、Obagi Medical製品、ヒアルロン酸ベースの皮膚フィラーART FILLER、皮内注入装置MicronJetの販売も行っている。また、カンタブリア・ラボ社とは商業化ライセンス契約を、太郎製薬社とは開発・商業化ライセンス契約を結んでいる。Crescita Therapeutics Inc.は2016年に法人化され、カナダのラバルに本社を置いている。もっと見るCrescita Therapeutics Inc. 基礎のまとめCrescita Therapeutics の収益と売上を時価総額と比較するとどうか。CRRT.F 基礎統計学時価総額US$10.63m収益（TTM）-US$231.28k売上高(TTM)US$16.78m0.6xP/Sレシオ-46.0xPER（株価収益率CRRT.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CRRT.F 損益計算書（TTM）収益CA$23.22m売上原価CA$11.04m売上総利益CA$12.18mその他の費用CA$12.50m収益-CA$320.00k直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.017グロス・マージン52.47%純利益率-1.38%有利子負債／自己資本比率0%CRRT.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/03 11:48終値2026/05/27 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Crescita Therapeutics Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 04ClinActiv Holdings Inc. completed the acquisition of Crescita Therapeutics Inc. (TSX:CTX).ClinActiv Holdings Inc. entered into a definitive arrangement agreement to acquire Crescita Therapeutics Inc. (TSX:CTX) for CAD 15.4 million on March 14, 2026. A cash consideration of CAD 15.4 million valued at CAD 0.8 per share will be paid by the buyer, subject to upward or downward adjustment based on the Company’s net working capital balance at the closing of the Arrangement, subject to a minimum purchase price of CAD 0.75 per Share. As part of consideration, CAD 15.4 million is paid towards common equity of Crescita Therapeutics Inc. The Arrangement Agreement includes a termination fee of CAD 2.0 million, and reverse termination fee of CAD 2.1 million ($1.5 million). The deal is subject to approval by shareholders of Crescita Therapeutics Inc. and receipt of court approval, and other customary conditions, Dissent Rights and minimum closing net cash. The transaction has been unanimously approved by the board of directors of Crescita Therapeutics and recommended that shareholders vote for the arrangement. The Arrangement is conditional on the Company having minimum cash and net working capital balances at closing. The deal is expected to close in the second quarter of 2026. As of April 22, 2026, Crescita Therapeutics Inc. filed and mailed shareholder meeting materials in connection with a special meeting to be held on May 14, 2026, seeking shareholder approval of the proposed arrangement with ClinActiv Holdings Inc. On May 14, 2026, the shareholders of Crescita Therapeutics approved the transaction. On May 20, 2026, Crescita Therapeutics Inc. announced that it has obtained a final court order from the Ontario Superior Court of Justice (Commercial List) approving the transaction. Upon closing of the arrangement, it is expected that the Crescita Therapeutics shares will be delisted from the Toronto Stock Exchange and that it will apply to the applicable Canadian securities regulators to cease to be a reporting issuer under applicable Canadian securities laws. As of June 1, 2026, the final consideration payable to the shareholders of Crescita is $0.8 per share and the transaction is expected to close on June 3, 2026. Bloom Burton Securities Inc. acted as financial advisor and fairness opinion provider for Crescita Therapeutics Inc. Chris Sunstrum of Goodmans LLP acted as legal advisor for Crescita Therapeutics Inc. BCF LLP acted as legal advisor for Crescita Therapeutics Inc. Aaron Sonshine of Bennett Jones LLP is acting as legal advisor to ClinActiv Holdings. TSX Trust Company acted as depositary bank to Crescita Therapeutics. ClinActiv Holdings Inc. completed the acquisition of Crescita Therapeutics Inc. (TSX:CTX) on June 3, 2026.
お知らせ • May 17Crescita Therapeutics Expects its Shares to Be Delisted from the Toronto Stock Exchange Upon Closing of the ArrangementCrescita Therapeutics Inc. (the “Company”) announced that at its special meeting (the “Meeting”) of shareholders (the “Shareholders”) held in person on May 14, 2026, Shareholders voted overwhelmingly in favour of the special resolution (the “Arrangement Resolution”) approving the previously announced plan of arrangement (the “Arrangement”) involving the Company, ClinActiv Holdings Inc. and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser will acquire all of the issued and outstanding common shares of the Company (the “Shares”) in exchange for all-cash consideration, subject to the terms and conditions of the arrangement agreement dated March 14, 2026 (the “Arrangement Agreement”). The final order of the Ontario Superior Court of Justice (Commercial List) approving the Arrangement will be sought on May 20, 2026. Completion of the Arrangement remains subject to receipt of the final order, the Company having the minimum cash and net working capital balances at closing, as well as other customary closing conditions. As of May 14, 2026, the Company anticipates that the Arrangement will be completed in the second quarter of 2026. Upon closing of the Arrangement, it is expected that the Shares will be delisted from the Toronto Stock Exchange and that the Company will apply to the applicable Canadian securities regulators to cease to be a reporting issuer under applicable Canadian securities laws.
お知らせ • Mar 16ClinActiv Holdings Inc. entered into a definitive arrangement agreement to acquire Crescita Therapeutics Inc. (TSX:CTX) for CAD 15.4 million.ClinActiv Holdings Inc. entered into a definitive arrangement agreement to acquire Crescita Therapeutics Inc. (TSX:CTX) for CAD 15.4 million on March 16, 2026. A cash consideration of CAD 15.4 million valued at CAD 0.8 per share will be paid by the buyer, subject to upward or downward adjustment based on the Company’s net working capital balance at the closing of the Arrangement, subject to a minimum purchase price of CAD 0.75 per Share. As part of consideration, CAD 15.4 million is paid towards common equity of Crescita Therapeutics Inc. The Arrangement Agreement includes a termination fee of CAD 2.0 million, and reverse termination fee of CAD 2.1 million ($1.5 million). The deal is subject to approval by shareholders of Crescita Therapeutics Inc. and receipt of court approval, and other customary conditions. The Arrangement is conditional on the Company having minimum cash and net working capital balances at closing. The Board of Crescita Therapeutics Inc unanimously recommended that shareholders vote FOR the Arrangement. The deal is is expected to close in the second quarter of 2026. Bloom Burton Securities Inc. acted as financial advisor and fairness opinion provider for Crescita Therapeutics Inc. Goodmans LLP acted as legal advisor for Crescita Therapeutics Inc. BCF LLP acted as legal advisor for Crescita Therapeutics Inc. Bennett Jones LLP is acting as legal advisor to ClinActiv Holdings.
お知らせ • Mar 17Crescita Therapeutics Inc., Annual General Meeting, Jun 04, 2025Crescita Therapeutics Inc., Annual General Meeting, Jun 04, 2025.
お知らせ • Jun 27Crescita Therapeutics Inc. (TSX:CTX) completed the acquisition of Assets of Occy Laboratory for CAD 0.9 million.Crescita Therapeutics Inc. (TSX:CTX) agreed to acquire Assets of Occy Laboratory on June 20, 2024.The transaction was approved by the bankruptcy court, is subject only to customary closing conditions, and is expected to close thereafter. Crescita Therapeutics Inc. (TSX:CTX) completed the acquisition of Assets of Occy Laboratory for CAD 0.9 million on June 26, 2024.
お知らせ • Mar 15Crescita Therapeutics Inc., Annual General Meeting, Jun 05, 2024Crescita Therapeutics Inc., Annual General Meeting, Jun 05, 2024.
お知らせ • Jun 04ClinActiv Holdings Inc. completed the acquisition of Crescita Therapeutics Inc. (TSX:CTX).ClinActiv Holdings Inc. entered into a definitive arrangement agreement to acquire Crescita Therapeutics Inc. (TSX:CTX) for CAD 15.4 million on March 14, 2026. A cash consideration of CAD 15.4 million valued at CAD 0.8 per share will be paid by the buyer, subject to upward or downward adjustment based on the Company’s net working capital balance at the closing of the Arrangement, subject to a minimum purchase price of CAD 0.75 per Share. As part of consideration, CAD 15.4 million is paid towards common equity of Crescita Therapeutics Inc. The Arrangement Agreement includes a termination fee of CAD 2.0 million, and reverse termination fee of CAD 2.1 million ($1.5 million). The deal is subject to approval by shareholders of Crescita Therapeutics Inc. and receipt of court approval, and other customary conditions, Dissent Rights and minimum closing net cash. The transaction has been unanimously approved by the board of directors of Crescita Therapeutics and recommended that shareholders vote for the arrangement. The Arrangement is conditional on the Company having minimum cash and net working capital balances at closing. The deal is expected to close in the second quarter of 2026. As of April 22, 2026, Crescita Therapeutics Inc. filed and mailed shareholder meeting materials in connection with a special meeting to be held on May 14, 2026, seeking shareholder approval of the proposed arrangement with ClinActiv Holdings Inc. On May 14, 2026, the shareholders of Crescita Therapeutics approved the transaction. On May 20, 2026, Crescita Therapeutics Inc. announced that it has obtained a final court order from the Ontario Superior Court of Justice (Commercial List) approving the transaction. Upon closing of the arrangement, it is expected that the Crescita Therapeutics shares will be delisted from the Toronto Stock Exchange and that it will apply to the applicable Canadian securities regulators to cease to be a reporting issuer under applicable Canadian securities laws. As of June 1, 2026, the final consideration payable to the shareholders of Crescita is $0.8 per share and the transaction is expected to close on June 3, 2026. Bloom Burton Securities Inc. acted as financial advisor and fairness opinion provider for Crescita Therapeutics Inc. Chris Sunstrum of Goodmans LLP acted as legal advisor for Crescita Therapeutics Inc. BCF LLP acted as legal advisor for Crescita Therapeutics Inc. Aaron Sonshine of Bennett Jones LLP is acting as legal advisor to ClinActiv Holdings. TSX Trust Company acted as depositary bank to Crescita Therapeutics. ClinActiv Holdings Inc. completed the acquisition of Crescita Therapeutics Inc. (TSX:CTX) on June 3, 2026.
お知らせ • May 17Crescita Therapeutics Expects its Shares to Be Delisted from the Toronto Stock Exchange Upon Closing of the ArrangementCrescita Therapeutics Inc. (the “Company”) announced that at its special meeting (the “Meeting”) of shareholders (the “Shareholders”) held in person on May 14, 2026, Shareholders voted overwhelmingly in favour of the special resolution (the “Arrangement Resolution”) approving the previously announced plan of arrangement (the “Arrangement”) involving the Company, ClinActiv Holdings Inc. and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser will acquire all of the issued and outstanding common shares of the Company (the “Shares”) in exchange for all-cash consideration, subject to the terms and conditions of the arrangement agreement dated March 14, 2026 (the “Arrangement Agreement”). The final order of the Ontario Superior Court of Justice (Commercial List) approving the Arrangement will be sought on May 20, 2026. Completion of the Arrangement remains subject to receipt of the final order, the Company having the minimum cash and net working capital balances at closing, as well as other customary closing conditions. As of May 14, 2026, the Company anticipates that the Arrangement will be completed in the second quarter of 2026. Upon closing of the Arrangement, it is expected that the Shares will be delisted from the Toronto Stock Exchange and that the Company will apply to the applicable Canadian securities regulators to cease to be a reporting issuer under applicable Canadian securities laws.
お知らせ • Mar 16ClinActiv Holdings Inc. entered into a definitive arrangement agreement to acquire Crescita Therapeutics Inc. (TSX:CTX) for CAD 15.4 million.ClinActiv Holdings Inc. entered into a definitive arrangement agreement to acquire Crescita Therapeutics Inc. (TSX:CTX) for CAD 15.4 million on March 16, 2026. A cash consideration of CAD 15.4 million valued at CAD 0.8 per share will be paid by the buyer, subject to upward or downward adjustment based on the Company’s net working capital balance at the closing of the Arrangement, subject to a minimum purchase price of CAD 0.75 per Share. As part of consideration, CAD 15.4 million is paid towards common equity of Crescita Therapeutics Inc. The Arrangement Agreement includes a termination fee of CAD 2.0 million, and reverse termination fee of CAD 2.1 million ($1.5 million). The deal is subject to approval by shareholders of Crescita Therapeutics Inc. and receipt of court approval, and other customary conditions. The Arrangement is conditional on the Company having minimum cash and net working capital balances at closing. The Board of Crescita Therapeutics Inc unanimously recommended that shareholders vote FOR the Arrangement. The deal is is expected to close in the second quarter of 2026. Bloom Burton Securities Inc. acted as financial advisor and fairness opinion provider for Crescita Therapeutics Inc. Goodmans LLP acted as legal advisor for Crescita Therapeutics Inc. BCF LLP acted as legal advisor for Crescita Therapeutics Inc. Bennett Jones LLP is acting as legal advisor to ClinActiv Holdings.
お知らせ • Mar 17Crescita Therapeutics Inc., Annual General Meeting, Jun 04, 2025Crescita Therapeutics Inc., Annual General Meeting, Jun 04, 2025.
お知らせ • Jun 27Crescita Therapeutics Inc. (TSX:CTX) completed the acquisition of Assets of Occy Laboratory for CAD 0.9 million.Crescita Therapeutics Inc. (TSX:CTX) agreed to acquire Assets of Occy Laboratory on June 20, 2024.The transaction was approved by the bankruptcy court, is subject only to customary closing conditions, and is expected to close thereafter. Crescita Therapeutics Inc. (TSX:CTX) completed the acquisition of Assets of Occy Laboratory for CAD 0.9 million on June 26, 2024.
お知らせ • Mar 15Crescita Therapeutics Inc., Annual General Meeting, Jun 05, 2024Crescita Therapeutics Inc., Annual General Meeting, Jun 05, 2024.
